Literature DB >> 7512159

The tat/rev intron of human immunodeficiency virus type 1 is inefficiently spliced because of suboptimal signals in the 3' splice site.

A Staffa1, A Cochrane.   

Abstract

Proportional expression of retroviral genes requires that splicing of the viral primary transcript be an inefficient process. Much of our current knowledge about retroviral suboptimal splicing comes from studies with Rous sarcoma virus. In this report, we describe the use of chimeric introns composed of human beta-globin and human immunodeficiency virus type 1 (HIV-1) splice sites to establish the basis for inefficient splicing of the intron which comprises most of the HIV-1 env coding sequences (referred to as the tat/rev intron). S1 RNA analysis of transfected COS-7 cells revealed that the 3' splice site (3' ss) of this region was significantly less efficient than the 3' ss of the first intron of beta-globin. Deletion of sequences flanking the tat/rev intron 3' ss demonstrated that the requirements for its inefficiency reside within the region that is expected to comprise the essential signals for splicing (i.e., the branchpoint region, the polypyrimidine tract, and the AG dinucleotide). Introduction of an exact copy of the efficient beta-globin branchpoint sequence within a highly conserved region rendered the tat/rev intron 3' ss highly efficient. Improvement of the polypyrimidine tract also increased the splicing efficiency, but to a degree slightly less than that obtained with the branchpoint mutation. Subsequent examination of the tat/rev intron 5' splice site in a heterologous context revealed that it is efficiently utilized. These results indicate that both a poor branchpoint region and a poor polypyrimidine tract are responsible for the low splicing efficiency of the HIV-1 tat/rev intron. It is of fundamental interest to establish the basis for inefficient splicing of the HIV-1 tat/rev intron since it may provide the key to understanding why nuclear export of mRNAs encoding HIV-1 structural proteins is Rev dependent.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7512159      PMCID: PMC236797     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  45 in total

1.  Characterization of Rous sarcoma virus intronic sequences that negatively regulate splicing.

Authors:  M T McNally; R R Gontarek; K Beemon
Journal:  Virology       Date:  1991-11       Impact factor: 3.616

2.  The role of branchpoint and 3'-exon sequences in the control of balanced splicing of avian retrovirus RNA.

Authors:  X D Fu; R A Katz; A M Skalka; T Maniatis
Journal:  Genes Dev       Date:  1991-02       Impact factor: 11.361

3.  The trans-activator gene of the human T cell lymphotropic virus type III is required for replication.

Authors:  A I Dayton; J G Sodroski; C A Rosen; W C Goh; W A Haseltine
Journal:  Cell       Date:  1986-03-28       Impact factor: 41.582

Review 4.  Human immunodeficiency virus as a prototypic complex retrovirus.

Authors:  B R Cullen
Journal:  J Virol       Date:  1991-03       Impact factor: 5.103

5.  Distinct RNA sequences in the gag region of human immunodeficiency virus type 1 decrease RNA stability and inhibit expression in the absence of Rev protein.

Authors:  S Schwartz; B K Felber; G N Pavlakis
Journal:  J Virol       Date:  1992-01       Impact factor: 5.103

6.  Identification of posttranscriptionally active inhibitory sequences in human immunodeficiency virus type 1 RNA: novel level of gene regulation.

Authors:  F Maldarelli; M A Martin; K Strebel
Journal:  J Virol       Date:  1991-11       Impact factor: 5.103

7.  Identification and characterization of intragenic sequences which repress human immunodeficiency virus structural gene expression.

Authors:  A W Cochrane; K S Jones; S Beidas; P J Dillon; A M Skalka; C A Rosen
Journal:  J Virol       Date:  1991-10       Impact factor: 5.103

8.  Intronic sequences and 3' splice sites control Rous sarcoma virus RNA splicing.

Authors:  M T McNally; K Beemon
Journal:  J Virol       Date:  1992-01       Impact factor: 5.103

9.  DNA sequencing with chain-terminating inhibitors.

Authors:  F Sanger; S Nicklen; A R Coulson
Journal:  Proc Natl Acad Sci U S A       Date:  1977-12       Impact factor: 11.205

10.  Trans-activator gene of human T-lymphotropic virus type III (HTLV-III).

Authors:  S K Arya; C Guo; S F Josephs; F Wong-Staal
Journal:  Science       Date:  1985-07-05       Impact factor: 47.728

View more
  52 in total

1.  The hnRNP A1 protein regulates HIV-1 tat splicing via a novel intron silencer element.

Authors:  T O Tange; C K Damgaard; S Guth; J Valcárcel; J Kjems
Journal:  EMBO J       Date:  2001-10-15       Impact factor: 11.598

2.  A novel function for Sam68: enhancement of HIV-1 RNA 3' end processing.

Authors:  Meredith McLaren; Kengo Asai; Alan Cochrane
Journal:  RNA       Date:  2004-07       Impact factor: 4.942

3.  A naturally arising mutation of a potential silencer of exon splicing in human immunodeficiency virus type 1 induces dominant aberrant splicing and arrests virus production.

Authors:  M P Wentz; B E Moore; M W Cloyd; S M Berget; L A Donehower
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

Review 4.  Idiosyncrasies of hnRNP A1-RNA recognition: Can binding mode influence function.

Authors:  Jeffrey D Levengood; Blanton S Tolbert
Journal:  Semin Cell Dev Biol       Date:  2018-04-09       Impact factor: 7.727

5.  Avian retroviral RNA element promotes unspliced RNA accumulation in the cytoplasm.

Authors:  R A Ogert; L H Lee; K L Beemon
Journal:  J Virol       Date:  1996-06       Impact factor: 5.103

6.  Inhibition of human immunodeficiency virus (HIV-1) infection in human peripheral blood leucocytes-SCID reconstituted mice by rapamycin.

Authors:  F Nicoletti; C Lapenta; C Lamenta; S Donati; M Spada; A Ranazzi; B Cacopardo; K Mangano; F Belardelli; C Perno; S Aquaro
Journal:  Clin Exp Immunol       Date:  2009-01       Impact factor: 4.330

7.  The exon splicing silencer in human immunodeficiency virus type 1 Tat exon 3 is bipartite and acts early in spliceosome assembly.

Authors:  Z H Si; D Rauch; C M Stoltzfus
Journal:  Mol Cell Biol       Date:  1998-09       Impact factor: 4.272

8.  Phosphorylation-dephosphorylation differentially affects activities of splicing factor ASF/SF2.

Authors:  S H Xiao; J L Manley
Journal:  EMBO J       Date:  1998-11-02       Impact factor: 11.598

9.  Inhibitory activity of the equine infectious anemia virus major 5' splice site in the absence of Rev.

Authors:  W Tan; M Schalling; C Zhao; M Luukkonen; M Nilsson; E M Fenyö; G N Pavlakis; S Schwartz
Journal:  J Virol       Date:  1996-06       Impact factor: 5.103

10.  Selection and characterization of replication-competent revertants of a Rous sarcoma virus src gene oversplicing mutant.

Authors:  L Zhang; S B Simpson; C M Stoltzfus
Journal:  J Virol       Date:  1996-06       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.